ACVRL1
Serine/threonine-protein kinase receptor R3
Protein Summary
Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bind activin as well. This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hemorrhagic telangie ...more
- ENST00000388922
- ENSP00000373574
- ENSG00000139567
- ACVRLK1
- ALK1
- HHT
- ALK1
- HHT2
- ORW2
- SKR3
- ALK-1
- TSR-I
- ACVRLK1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological process | 1 | ||
molecular function | 1 | ||
protein domain | 0.92 | ||
disease perturbation | 0.79 | ||
biological term | 0.78 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 447.72 (req: < 5)
Gene RIFs: 140 (req: <= 3)
Antibodies: 540 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 447.72 (req: >= 5)
Gene RIFs: 140 (req: > 3)
Antibodies: 540 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 60
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 54
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0